869489-04-3 Usage
Uses
Used in Pharmaceutical Industry:
(S)-4,4-difluoropyrrolidine-2-carbonitrile hydrochloride is utilized as a key intermediate in the synthesis of pharmaceutical drugs for various medical conditions. Its unique chemical structure and properties contribute to the development of new and effective treatments.
Used in Drug Synthesis:
In the field of drug synthesis, (S)-4,4-difluoropyrrolidine-2-carbonitrile hydrochloride is employed as a crucial building block for creating pharmaceutical compounds with potential therapeutic benefits. Its hydrochloride form enhances the stability and solubility of the compound, facilitating its use in the production of drugs.
Used in Research and Development:
(S)-4,4-difluoropyrrolidine-2-carbonitrile hydrochloride is also used in research and development settings to explore its potential applications in the creation of novel pharmaceutical products and to study its interactions with other compounds for the development of innovative drug therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 869489-04-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,9,4,8 and 9 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 869489-04:
(8*8)+(7*6)+(6*9)+(5*4)+(4*8)+(3*9)+(2*0)+(1*4)=243
243 % 10 = 3
So 869489-04-3 is a valid CAS Registry Number.
869489-04-3Relevant academic research and scientific papers
INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
-
, (2019/07/03)
Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
Therapeutic compounds
-
Page/Page column 14, (2008/06/13)
The invention provides compounds of formula (I), prodrugs and stereoisomers thereof, and the pharmaceutically acceptable salts of the compounds, prodrugs, and stereoisomers, wherein R1, R2, R3, HET, n, Q, X, Y, and Z are as described herein; compositions thereof; and uses thereof in treating diabetic complications including diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, and the like.
